share_log

UBS Initiates Coverage On 10x Genomics With Neutral Rating, Announces Price Target of $50

UBS Initiates Coverage On 10x Genomics With Neutral Rating, Announces Price Target of $50

瑞银以中性评级开始报道10倍基因组学,宣布目标价为50美元
Benzinga Real-time News ·  2023/02/02 08:44

UBS analyst John Sourbeer initiates coverage on 10x Genomics (NASDAQ:TXG) with a Neutral rating and announces Price Target of $50.

瑞银分析师John Sourmer对10倍基因组(纳斯达克:TXG)发起报道,评级为中性,并宣布目标价为50美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发